Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Medtronic
Johnson and Johnson
Harvard Business School
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,141,581

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,141,581 protect, and when does it expire?

Patent 7,141,581 protects INLYTA and is included in one NDA.

This patent has eighty-three patent family members in fifty-two countries.

Summary for Patent: 7,141,581
Title:Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s): Bender; Steven (Oceanside, CA), Hu-Lowe; Dana (Encinitas, CA), Shalinsky; David Ray (San Diego, CA)
Assignee: Agouron Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/639,890
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,141,581

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No   Start Trial   Start Trial TREATMENT OF RENAL CELL CARCINOMA   Start Trial
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes   Start Trial   Start Trial TREATMENT OF RENAL CELL CARCINOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,141,581

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1486   Start Trial
Argentina 035554   Start Trial
Argentina 065937   Start Trial
Austria 376543   Start Trial
Australia 5785200   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
Moodys
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.